Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption
Acquiring Company
Quest Diagnostics
Acquired Company
PathAI
Description
Quest Diagnostics, a leader in diagnostic information services, has announced a multi-faceted collaboration with PathAI to accelerate the adoption of digital and AI pathology innovations, with the acquisition of select assets of PathAI Diagnostics. This collaboration aims to improve the quality, speed, and efficiency in diagnosing cancer and other diseases, leveraging Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations.
Quick answer
Quest Diagnostics is acquiring PathAI, announced May 1, 2024. Quest Diagnostics is based in Secaucus, New Jersey, United States.
- How much did Quest Diagnostics pay for PathAI?
- The deal value was not disclosed.
- What does Quest Diagnostics do?
- Quest Diagnostics empowers people to take action to improve health outcomes.
- Where are Quest Diagnostics and PathAI based?
- Quest Diagnostics is based in Secaucus, New Jersey, United States. PathAI is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Quest Diagnostics?
- Fundz holds 2 contacts at Quest Diagnostics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Data And Analytics and Health Diagnostics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- HEALWELL AI Inc. to Acquire VeroSource Solutions Inc. for AI-Powered Population Health Capabilities (June 11, 2024)
- RenovaroCube completes acquisition of Cyclomics to advance cutting-edge cancer diagnostics (April 24, 2024)
- EPAM Systems, Inc. acquires Odysseus Data Services, Inc. to transform the Life Sciences Value Chain (June 13, 2024)
- Simulations Plus completes acquisition of Pro-ficiency Holdings, Inc. to enhance drug development solutions (June 12, 2024)
- Health Catalyst, Inc. completes acquisition of Carevive Systems to enhance oncology-focused health technology (June 6, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
Who to call at Quest Diagnostics, and when
When Quest Diagnostics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Quest Diagnostics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Quest Diagnostics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Quest Diagnostics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Quest Diagnostics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired PathAI?
PathAI was acquired by Quest Diagnostics, based in Secaucus. The deal was reported on May 1, 2024. Quest Diagnostics empowers people to take action to improve health outcomes. Quest Diagnostics is publicly traded (DGX) and operates in Data And Analytics.
When did Quest Diagnostics acquire PathAI?
Quest Diagnostics's acquisition of PathAI was reported on May 1, 2024. Quest Diagnostics, a leader in diagnostic information services, has announced a multi-faceted collaboration with PathAI to accelerate the adoption of digital and AI pathology innovations, with the acquisition of select assets of PathAI Diagnostics. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does PathAI do?
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. It is privately held, operating in Information Technology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.